匹立昔尔

Pirinixil 是一种低毒性降血脂药。

信号通路 >> 其他 >> 其他

研究领域 >> 代谢疾病

Pirinixil是一种低毒的降血脂药。 Pirinixi在大鼠的脾脏,肾脏和心脏中降低总胆固醇。 Pirinixil使估计的总体内胆固醇降低约40％[1]。 Pirinixil可显着提高血浆胆固醇水平,而不会影响血浆甘油三酯。 Pirinixil显着降低肝脏胆固醇和甘油三酯,而血浆和肝脏脂质水平降低约20％。肝脏HMG-CoA还原酶活性不受影响,但Pirinixil可显着降低胆固醇7α-羟化酶[2]。

在所有研究中使用在每个实验开始时重220-230g的雄性Sprague-Dawley大鼠。它们被保存在空调环境中，拥有可控的照明和免费供水。膳食治疗是（A）大鼠的标准饮食和（B）2％胆固醇+ 2％胆酸方案。两种饮食分别随意给药1周和2周（标准饮食）和2周（胆固醇酸饮食）。在3个实验的每一个中的5只大鼠组（标准饮食1周和2周，胆固醇 - 胆酸饮食2周）通过胃插管每天在羧甲基纤维素载体中以20mg / kg的剂量施用Pirinixil。通过插管[1]每天给予对照相似体积的载体。

[1]. D'Atri G, et al. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83.

[2]. Kritchevsky D, et al. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil(BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82.

磺丁基-β-环糊精钠盐 | 环孢霉素A | 2-(3,6-二乙酰氧基-2,7-二氯-9H-氧杂蒽-9-基)苯甲酸 | 1-甲基-4-苯基-1,2,3,6-四氢吡啶盐酸盐 | GW4869 | 乙莫克舍 | (2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-硫代双(4-(4-(3-氟苯基)-1H-1,-1H-1,2,3-三唑-1-基)-2-(羟甲基)四氢-2H-吡喃-3,5-二醇) | Mitoquinone甲磺酸盐 | GSK2795039 | CBIC2 | BAPTA-AM | AP20187 | GKT137831 | D-(-)-荧光素 | 单响尾蛇毒蛋白

DATA ITEMS CITED :

7

MOLECULAR FORMULA :

C16-H19-Cl-N4-O2-S

MOLECULAR WEIGHT :

366.90

WISWESSER LINE NOTATION :

T6M CN BHJ BS1VM2Q DG FMR B1 C1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

>5 gm/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

>5 gm/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

1575 mg/kg/21D-C

TOXIC EFFECTS :

Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - catalases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other transferases

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

17 gm/kg/81W-C

TOXIC EFFECTS :

Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other transferases

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

137 gm/kg/81W-C

TOXIC EFFECTS :

Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors

MUTATION DATA

TYPE OF TEST :

DNA inhibition

TEST SYSTEM :

Rodent - mouse Cells - not otherwise specified

DOSE/DURATION :

25 umol/L

REFERENCE :

CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 40,36,1980